8 recruiting, 4 not yet recruiting, 3 terminated, 1 active not recruiting. 11 Phase 2, 3 Not applicable, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow DEAE-Dextran: new trials by email Literature Review of DEAE-Dextran trials Research Report on DEAE-Dextran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC) | Phase 3 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-12-01 | 2026-10-26 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy), PULSAR - Gastric Adenocarcinoma, Stomach Neoplasms | Not applicable | Recruiting | Samsung Medical Center | 53 | 2026-05-15 | 2026-05-28 |
| PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy Tislelizumab Combined With TKI, Fecal Microbiota Transplantation, PULSAR - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Wang Xin | 64 | 2026-04-15 | 2026-09-02 |
| NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NALIRIFOX+Adebrelimab, PULSAR - Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 55 | 2026-04-01 | 2026-05-19 |
| Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Nivolumab, Ipilimumab (1mg/kg), PULSAR - Colorectal Cancer (MSI-H) | Phase 2 | Not yet recruiting | Fudan University | 114 | 2026-02-01 | 2026-02-11 |
| PULSAR Combined With Immunotherapy and Chemotherapy Iparomlimab and Tuvonralimab Injection (QL1706), PULSAR - Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Wang Xin | 60 | 2025-11-04 | 2025-12-18 |
| Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR) - Cancer, Lung, Metastasis | Early Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2025-09-19 | 2026-06-29 |
| Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy Elacestrant, PULSAR - Breast Cancer Patients, Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria Careggi | 21 | 2025-09-01 | 2025-06-05 |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal) Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography - Head and Neck Carcinoma, Localized Head and Neck Carcinoma | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 43 | 2024-10-25 | 2026-02-05 |
| PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients PD-1, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 2 | Recruiting | Fudan University | 81 | 2024-06-01 | 2024-06-25 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies IMSA101, Immune checkpoint inhibitor, PULSAR - Oligoprogressive | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 16 | 2023-07-07 | 2026-05-15 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC IMSA101, Immune checkpoint inhibitor, PULSAR - Oligometastatic Disease | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 6 | 2023-06-28 | 2025-10-20 |
| Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer personalized ultrafractionated stereotactic ablative radiotherapy - Bladder Cancer | Not applicable | Terminated | University of Texas Southwestern Medical Center | 1 | 2021-09-06 | 2024-02-06 |
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Lymphatic Metastasis (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Stomach Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Thyroid Neoplasms (1) · Turcot syndrome (1)
Fudan University (2) · ImmuneSensor Therapeutics Inc. (2) · Samsung Medical Center (2) · University of Texas Southwestern Medical Center (2) · Wang Xin (2) · West China Hospital (2) · Azienda Ospedaliero-Universitaria Careggi (1) · Jonsson Comprehensive Cancer Center (1) · University Health Network, Toronto (1) · Washington University School of Medicine (1)
China (6) · United States (6) · South Korea (2) · Canada (1) · Italy (1)
Patrick Widhelm (2) · Nikhil Rammohan, MD, PhD (1) · Solomon L Woldu, MD (1) · Travis Courtney, MD (1) · Weijing Zhang (1)
PMID 20842054, PMID 21561347, PMID 22658128, PMID 24131140, PMID 33794306, PMID 34439389, PMID 34726575, PMID 37280366, PMID 37459862, PMID 37708904, PMID 37820884, PMID 38572751, PMID 38589494, PMID 39008192, PMID 39089313, PMID 39448025, PMID 39687891, PMID 39709372, PMID 40204149
2025 (1)